Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Association
Breast cancer
Overall survival
Progression-free survival
Real-word data
Surrogacy
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
received:
04
07
2022
accepted:
25
01
2023
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
10
3
2023
Statut:
epublish
Résumé
Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification). We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype. 20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies. Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates.
Sections du résumé
BACKGROUND
Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification).
METHODS
We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype.
RESULTS
20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies.
CONCLUSIONS
Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates.
Identifiants
pubmed: 36882736
doi: 10.1186/s12916-023-02754-5
pii: 10.1186/s12916-023-02754-5
pmc: PMC9993797
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Informations de copyright
© 2023. The Author(s).
Références
Ther Adv Med Oncol. 2021 Jan 21;13:1758835920987657
pubmed: 33613700
Clin Breast Cancer. 2021 Aug;21(4):292-301
pubmed: 33309481
ESMO Open. 2019 Sep 08;4(5):e000562
pubmed: 31555487
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2008 Nov 18;99(10):1572-8
pubmed: 19002178
N Engl J Med. 2000 Jun 22;342(25):1878-86
pubmed: 10861324
Cancer J. 2009 Sep-Oct;15(5):401-5
pubmed: 19826360
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Eur J Cancer. 2020 Apr;129:60-70
pubmed: 32135312
Br J Cancer. 2019 Dec;121(12):991-1000
pubmed: 31719684
Eur J Cancer. 2020 Jan;125:22-30
pubmed: 31835235
BMJ Open. 2019 Feb 21;9(2):e023568
pubmed: 30796119
Crit Rev Oncol Hematol. 2002 May;42(2):137-43
pubmed: 12007971
N Engl J Med. 2011 Jul 14;365(2):e3
pubmed: 21707383
Breast Cancer Res Treat. 2014 Jun;145(3):725-34
pubmed: 24706168
Ann Oncol. 2016 Sep;27(9):1725-32
pubmed: 27436849
Oncologist. 2020 Feb;25(2):e214-e222
pubmed: 32043771
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Breast Cancer Res Treat. 2022 Feb;191(3):577-587
pubmed: 34984582
J Clin Oncol. 2017 Jun 1;35(16):1845-1854
pubmed: 28358653
Ann Oncol. 2015 May;26(5):873-879
pubmed: 25725046
Ther Adv Med Oncol. 2020 Dec 23;12:1758835920980548
pubmed: 33488779
BMC Cancer. 2019 Jan 18;19(1):88
pubmed: 30658600
Crit Rev Oncol Hematol. 2018 Mar;123:21-41
pubmed: 29482777
Breast. 2021 Dec;60:138-146
pubmed: 34624756
Biometrics. 1995 Dec;51(4):1384-99
pubmed: 8589230
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
JAMA Oncol. 2022 May 1;8(5):679-680
pubmed: 35266952
Anticancer Res. 2020 Jul;40(7):3905-3913
pubmed: 32620631
JAMA Oncol. 2021 May 01;7(5):728-734
pubmed: 33764385
Ann Oncol. 2016 Jun;27(6):1029-1034
pubmed: 26961151
NPJ Breast Cancer. 2021 Apr 16;7(1):41
pubmed: 33863896
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2019 Dec 15;145(12):3359-3369
pubmed: 31087564
Eur J Cancer. 2018 Jun;96:17-24
pubmed: 29660596
J Clin Oncol. 2008 Apr 20;26(12):1987-92
pubmed: 18421050
Stat Med. 2013 Nov 30;32(27):4781-90
pubmed: 23775542
Biostatistics. 2000 Mar;1(1):49-67
pubmed: 12933525
Onco Targets Ther. 2014 Jun 18;7:1101-10
pubmed: 24971020
Clin Med Res. 2009 Jun;7(1-2):4-13
pubmed: 19574486
Med Oncol. 2014 Jan;31(1):776
pubmed: 24271313